| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 02/06/2002 | CN1334736A Modulation of immune response by ribavirin |
| 02/06/2002 | CN1334730A Vitronectin receptor antagonist |
| 02/06/2002 | CN1334726A Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists |
| 02/06/2002 | CN1334105A 'Bingshe' antalgesic plaster |
| 02/06/2002 | CN1334093A Medical use of phytosterone component in Radix Rhapontici |
| 02/06/2002 | CN1078889C Non-pepitde tachykinin receptor antagonists |
| 02/05/2002 | US6344570 Substituted urea derivatives as cell adhesion inhibitors |
| 02/05/2002 | US6344563 Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
| 02/05/2002 | US6344562 Thiazole derivatives |
| 02/05/2002 | US6344484 Treatment of tumor growth, metastasis, osteoporosis, restenosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis |
| 02/05/2002 | US6344455 Treating cancer, atherosclerosis, restenosis, endometriosis, and psoriasis |
| 02/05/2002 | US6344450 Lactam compounds and their use as inhibitors of serine proteases and method |
| 02/05/2002 | US6344449 Headache and morphine dependence |
| 02/05/2002 | US6344444 Arginine-silicate-inositol complex and use thereof |
| 02/05/2002 | US6344441 Lipoprotein-regulating medicaments |
| 02/05/2002 | US6344439 Agents for promoting bone formation |
| 02/05/2002 | US6344437 Medicine drink food and feed having an action of strengthening bone |
| 02/05/2002 | US6344339 Monoclonal antibodies against the extracellular domain of human VEGF-receptor protein (KDR) |
| 02/05/2002 | US6344321 Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met |
| 02/05/2002 | CA2218289C Cd45rb binding compounds for the prevention of transplant rejection |
| 01/31/2002 | WO2002008396A2 Human proteases |
| 01/31/2002 | WO2002008285A2 Il-17 molecules and uses thereof |
| 01/31/2002 | WO2002008272A2 High affinity soluble interleukin-18 receptor |
| 01/31/2002 | WO2002008271A1 Novel fibroblast growth factor (fgf23) and methods for use |
| 01/31/2002 | WO2002008255A2 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | WO2002008231A2 Biologically active macrolides, compositions, and uses thereof |
| 01/31/2002 | WO2002008222A2 HETEROARYL-β-ALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS |
| 01/31/2002 | WO2002008221A2 Capsaicin receptor ligands |
| 01/31/2002 | WO2002008217A2 COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS |
| 01/31/2002 | WO2002008213A1 Colchinol derivatives as angiogenesis inhibitors |
| 01/31/2002 | WO2002008210A1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 01/31/2002 | WO2002008189A1 Compounds and inhibitors of phospholipases |
| 01/31/2002 | WO2002007772A2 Improved oral dosage formulations |
| 01/31/2002 | WO2002007765A2 REGULATORS OF PPARδ(β) AND THEIR USE IN THE TREATMENT OF OBESITY AND INSULIN RESISTANCE |
| 01/31/2002 | WO2002007748A2 Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor |
| 01/31/2002 | WO2002007734A1 Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses |
| 01/31/2002 | WO2002007733A2 Method for enhancing bone mineral density gain by administration of raloxifene |
| 01/31/2002 | WO2002007730A1 Alpha v integrin receptor antagonists |
| 01/31/2002 | WO2002007725A1 Method for treating fibrotic diseases or other indications ic |
| 01/31/2002 | WO2002007720A1 Compounds having mif antagonist activity |
| 01/31/2002 | WO2002007719A1 Use of estramustine phosphate in the treatment of bone metastasis |
| 01/31/2002 | WO2002007673A2 Calcilytic compounds |
| 01/31/2002 | WO2001079158A3 Compounds for modulating cell proliferation |
| 01/31/2002 | WO2001070682A3 Carbocyclic side chain containing metalloprotease inhibitors |
| 01/31/2002 | WO2001062775A3 Novel antiarrhythmic peptides |
| 01/31/2002 | WO2001062341A3 Combination product for the treatment of obesity |
| 01/31/2002 | WO2001036605A3 2786, a human aminopeptidase |
| 01/31/2002 | WO2001034801A3 Recombinant gelatin in vaccines |
| 01/31/2002 | WO2000059941A9 Purposeful movement of human migratory cells away from an agent source |
| 01/31/2002 | US20020013459 Process for the preparation of macrocyclic metalloprotease inhibitors |
| 01/31/2002 | US20020013374 Administering compound effective to inhibit binding of an amyloid beta peptide with alpha-7 nicotinic acetylcholine receptors |
| 01/31/2002 | US20020013369 Certain 5-alkyl-2arylaminophenylacetic acids and derivatives |
| 01/31/2002 | US20020013357 Valdecoxib compositions |
| 01/31/2002 | US20020013354 p38 map kinase inhibitors |
| 01/31/2002 | US20020013349 Administering drug which opens potassium channel for reducing pain |
| 01/31/2002 | US20020013347 Tri-aryl-substituted-ethane PDE4 inhibitors |
| 01/31/2002 | US20020013341 For therapy of acute infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrtate deposition |
| 01/31/2002 | US20020013334 HMG-CoA reductase inhibitors and method |
| 01/31/2002 | US20020013321 Used as ligands for opioid receptors, for therapy of neurological and gastrointestinal disorders |
| 01/31/2002 | US20020013297 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators |
| 01/31/2002 | US20020013294 Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| 01/31/2002 | US20020013278 Using an interleukin-1 beta converting enzyme inhibitor pro-drug to treat apoptosis-, interferon-gamma inducing factor or interferon-gamma inducing diseases; antiinflammatory and -proliferative agents; autoimmune/degenerative disesesdiseases |
| 01/31/2002 | US20020013274 Administering a covalently reactive antigen analog (CRAA) having an an epitope recognized irreversibly bound by catalytic antibody; autoimmune disease; a lymphoproliferative disorder; anticarcinogenic, -tumor, -inflammatory agents |
| 01/31/2002 | US20020013259 Therapeutic and diagnostic methods for ulcerative colitis and associated disorders |
| 01/31/2002 | US20020013256 Novel inhibitors of formation of advanced glycation endproducts (AGES) |
| 01/31/2002 | US20020012962 Nucleotide sequences coding fusion protein for use in the treatment of osteoporosis, cancers, and cachexia |
| 01/31/2002 | US20020012696 In gene therapy and in in vitro and in vivo transfection |
| 01/31/2002 | US20020012690 For therapy of arthropathy, osteoarthritis, gonarthrosis, periarthritis scapulo-humeralis, spondylitis deformans, etc. and foods or drinks having the effect of preventing or alleviating joint pains, cinealgia |
| 01/31/2002 | DE10034802A1 Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren Stable salts of O-acetylsalicylic acid with basic amino acids |
| 01/31/2002 | CA2418215A1 Novel fibroblast growth factor (fgf23) and methods for use |
| 01/31/2002 | CA2417127A1 Compounds and inhibitors of phospholipases |
| 01/31/2002 | CA2417005A1 Regulators of ppar.delta.(.beta.) and their use in the treatment of obesity and insulin resistance |
| 01/31/2002 | CA2416751A1 Alpha v integrin receptor antagonists |
| 01/31/2002 | CA2416750A1 Compounds having mif antagonist activity |
| 01/31/2002 | CA2416691A1 Proteases |
| 01/31/2002 | CA2416537A1 Calcilytic compounds |
| 01/31/2002 | CA2416404A1 Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor |
| 01/31/2002 | CA2415606A1 Capsaicin receptor ligands |
| 01/31/2002 | CA2415362A1 Method for treating fibrotic diseases or other indications |
| 01/31/2002 | CA2415131A1 Improved oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea |
| 01/31/2002 | CA2415077A1 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | CA2415054A1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 01/31/2002 | CA2412626A1 Il-17 molecules and uses thereof |
| 01/31/2002 | CA2412392A1 Use of estramustine phosphate in the treatment of bone metastasis |
| 01/31/2002 | CA2412373A1 Method for enhancing bone mineral density gain |
| 01/31/2002 | CA2410562A1 Colchinol derivatives as angiogenesis inhibitors |
| 01/30/2002 | EP1176145A1 Novel guanidino derivatives as inhibitors of cell adhesion |
| 01/30/2002 | EP1175913A1 Intramuscular pharmaceutical composition comprising dexibuprofen and uses thereof |
| 01/30/2002 | EP1175904A2 Method for inhibiting bone resorption |
| 01/30/2002 | EP1175903A2 Method for inhibiting bone resorption |
| 01/30/2002 | EP1175900A2 Use of growth hormone secretagogues for improvement of fucnctional health status |
| 01/30/2002 | EP1175504A1 Dna encoding the human vanilloid receptor vr1 |
| 01/30/2002 | EP1175490A2 Tyrosine kinase substrate (tks) proteins |
| 01/30/2002 | EP1175446A1 Human antibodies that bind human il-12 and methods for producing |
| 01/30/2002 | EP1175444A1 Amino-terminal modified parathyroid hormone (pth) analogs |
| 01/30/2002 | EP1175442A2 Osteopontin-derived chemotactic and inhibitory agents and uses therefor |
| 01/30/2002 | EP1175433A1 Androgen glycosides and androgenic activity thereof |
| 01/30/2002 | EP1175417A1 Substituted benzolactam compounds |
| 01/30/2002 | EP1175412A1 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
| 01/30/2002 | EP1175408A1 Pyrimidinone compounds |